Cite
HARVARD Citation
Giugliano, R. et al. (2017). Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 390 (10106), pp. 1962-1971. [Online].